Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus

被引:43
作者
Souza, RF
Morales, CP
Spechler, SJ
机构
[1] Vet Adm Med Ctr, Dept Med, Dallas, TX 75216 USA
[2] Univ Texas, SW Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
关键词
D O I
10.1046/j.1365-2036.2001.01046.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Oesophageal adenocarcinoma is one of the most deadly human malignancies. Gastro-oesophageal reflux disease (GERD) has been established as a strong risk factor for oesophageal adenocarcinoma, and more than 40% of adult Americans experience regular GERD symptoms. GERD can be complicated by oesophagitis, and by replacement of oesophageal squamous mucosa with metaplastic, intestinal-type epithelium (Barrett's oesophagus) that is predisposed to malignancy. Cancers in Barrett's oesophagus arise through a sequence of genetic alterations which endow unlimited proliferative capacity upon the cells by affecting components of the cell cycle clock apparatus-the pivotal molecular machinery in the cell nucleus that controls whether a cell will proliferate, differentiate, become quiescent or die. This report describes how the genetic abnormalities that have been recognized in Barrett's oesophagus might promote carcinogenesis through effects on the cell cycle clock machinery. The goal of this review is to provide the clinician with a useful conceptual basis for evaluating studies on the molecular mechanisms underlying the progression from metaplasia to carcinoma in Barrett's oesophagus.
引用
收藏
页码:1087 / 1100
页数:14
相关论文
共 161 条
[41]  
Grady WM, 1999, CANCER RES, V59, P320
[42]   MUCOSAL POLYAMINE METABOLISM IN THE COLUMNAR LINED ESOPHAGUS [J].
GRAY, MR ;
WALLACE, HM ;
GOULDING, H ;
HOFFMAN, J ;
KENYON, WE ;
KINGSNORTH, AN .
GUT, 1993, 34 (05) :584-587
[43]   EPITHELIAL PROLIFERATION IN BARRETT-ESOPHAGUS BY PROLIFERATING CELL NUCLEAR ANTIGEN IMMUNOLOCALIZATION [J].
GRAY, MR ;
HALL, PA ;
NASH, J ;
ANSARI, B ;
LANE, DP ;
KINGSNORTH, AN .
GASTROENTEROLOGY, 1992, 103 (06) :1769-1776
[44]   Fas-ligand: Privilege and peril [J].
Green, DR ;
Ware, CF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) :5986-5990
[45]   REDUCED RISK OF LARGE-BOWEL ADENOMAS AMONG ASPIRIN USERS [J].
GREENBERG, ER ;
BARON, JA ;
FREEMAN, DH ;
MANDEL, JS ;
HAILE, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (11) :912-916
[46]  
Griffith TS, 1997, IMMUNOL TODAY, V18, P361
[47]  
Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO
[48]  
2-D
[49]   Aspirin, NSAIDs, and colon cancer prevention: Mechanisms? [J].
Gupta, RA ;
DuBois, RN .
GASTROENTEROLOGY, 1998, 114 (05) :1095-1098
[50]   TP53 GENE-MUTATIONS AND P53 PROTEIN IMMUNOREACTIVITY IN MALIGNANT AND PREMALIGNANT BARRETTS-ESOPHAGUS [J].
HAMELIN, R ;
FLEJOU, JF ;
MUZEAU, F ;
POTET, F ;
LAURENTPUIG, P ;
FEKETE, F ;
THOMAS, G .
GASTROENTEROLOGY, 1994, 107 (04) :1012-1018